AU2020371736A1 - Conjugates and methods for treating acromegaly - Google Patents
Conjugates and methods for treating acromegaly Download PDFInfo
- Publication number
- AU2020371736A1 AU2020371736A1 AU2020371736A AU2020371736A AU2020371736A1 AU 2020371736 A1 AU2020371736 A1 AU 2020371736A1 AU 2020371736 A AU2020371736 A AU 2020371736A AU 2020371736 A AU2020371736 A AU 2020371736A AU 2020371736 A1 AU2020371736 A1 AU 2020371736A1
- Authority
- AU
- Australia
- Prior art keywords
- sirna
- compound
- group
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962925659P | 2019-10-24 | 2019-10-24 | |
| US62/925,659 | 2019-10-24 | ||
| PCT/US2020/057185 WO2021081420A2 (en) | 2019-10-24 | 2020-10-23 | Conjugates and methods for treating acromegaly |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020371736A1 true AU2020371736A1 (en) | 2022-06-02 |
Family
ID=75620892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020371736A Abandoned AU2020371736A1 (en) | 2019-10-24 | 2020-10-23 | Conjugates and methods for treating acromegaly |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220288214A1 (https=) |
| EP (1) | EP4048801A4 (https=) |
| JP (1) | JP7668032B2 (https=) |
| CN (1) | CN114616339A (https=) |
| AU (1) | AU2020371736A1 (https=) |
| BR (1) | BR112022007725A2 (https=) |
| CA (1) | CA3158917A1 (https=) |
| IL (1) | IL292391A (https=) |
| WO (1) | WO2021081420A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3020585A1 (en) * | 2016-04-11 | 2017-10-19 | Arbutus Biopharma Corporation | Targeted nucleic acid conjugate compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2322651A1 (en) * | 2004-05-14 | 2011-05-18 | Rosetta Genomics Ltd | MicroRNAs and uses thereof |
| CA2917229A1 (en) * | 2013-07-02 | 2015-01-08 | Isis Pharmaceuticals, Inc. | Modulators of growth hormone receptor |
| BR112016022742B1 (pt) * | 2014-05-01 | 2022-06-14 | Ionis Pharmaceuticals, Inc | Composto químico, composição compreendendo o composto e uso dos mesmos |
| WO2015179693A1 (en) * | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP3151839A4 (en) * | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| EP3228326A1 (en) | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| DK3607069T3 (da) | 2017-04-05 | 2022-11-21 | Silence Therapeutics Gmbh | Produkter og sammensætninger |
| WO2018185253A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Ligand modified double-stranded nucleic acids |
| JP7406793B2 (ja) * | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | 2テイル自己デリバリー型siRNAおよび関連方法 |
| EP3775209A1 (en) * | 2018-04-05 | 2021-02-17 | Silence Therapeutics GmbH | Sirnas with at least two ligands at different ends |
-
2020
- 2020-10-23 CA CA3158917A patent/CA3158917A1/en active Pending
- 2020-10-23 WO PCT/US2020/057185 patent/WO2021081420A2/en not_active Ceased
- 2020-10-23 BR BR112022007725A patent/BR112022007725A2/pt unknown
- 2020-10-23 IL IL292391A patent/IL292391A/en unknown
- 2020-10-23 US US17/770,504 patent/US20220288214A1/en not_active Abandoned
- 2020-10-23 JP JP2022523585A patent/JP7668032B2/ja active Active
- 2020-10-23 AU AU2020371736A patent/AU2020371736A1/en not_active Abandoned
- 2020-10-23 CN CN202080075748.1A patent/CN114616339A/zh active Pending
- 2020-10-23 EP EP20879819.9A patent/EP4048801A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN114616339A (zh) | 2022-06-10 |
| IL292391A (en) | 2022-06-01 |
| EP4048801A4 (en) | 2023-11-22 |
| JP2022553056A (ja) | 2022-12-21 |
| WO2021081420A3 (en) | 2021-06-03 |
| JP7668032B2 (ja) | 2025-04-24 |
| EP4048801A2 (en) | 2022-08-31 |
| BR112022007725A2 (pt) | 2022-08-16 |
| US20220288214A1 (en) | 2022-09-15 |
| WO2021081420A2 (en) | 2021-04-29 |
| CA3158917A1 (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250179496A1 (en) | Targeted compositions | |
| JP2024175018A (ja) | 治療方法 | |
| WO2021113820A1 (en) | Conjugates and methods for treating liver fibrosis | |
| WO2019182109A1 (ja) | ヘテロ核酸のbbb通過脂質リガンド | |
| IL302530A (en) | Targeted conjugates involving modified siRNA | |
| JP7668032B2 (ja) | 先端巨大症を処置するためのコンジュゲート及び方法 | |
| HK40057109A (en) | Targeted compositions | |
| WO2026086824A1 (zh) | 双链寡核苷酸、缀合物和组合物以及它们的用途 | |
| WO2024165551A1 (en) | Modified nucleic acid conjugates for inhibiting gene expression | |
| NZ787057A (en) | Targeted nucleic acid conjugate compositions |